A synthetic GHRH analogue studied extensively for its selective ability to reduce visceral adiposity and stimulate pulsatile GH secretion with high receptor specificity.
Tesamorelin is a synthetic analogue of human GHRH with a trans-3-hexenoic acid group at the N-terminus. This modification protects the peptide from DPP-IV cleavage, significantly extending its biological half-life while preserving receptor-binding specificity for the pituitary GHRH receptor.
Research on Tesamorelin has been most extensive in HIV-associated lipodystrophy, where clinical trials demonstrated meaningful reductions in trunk and visceral fat — effects that appear selective compared to systemic GH administration. This selective visceral fat reduction has extended research interest to metabolic syndrome, non-alcoholic fatty liver disease, and age-related body composition changes.
The compound stimulates GH release through its native mechanism — pituitary GHRH receptor activation — producing pulsatile GH secretion patterns more physiologically similar to endogenous release than supraphysiological GH administration. Studies examining IGF-1 changes, lipid metabolism, and insulin sensitivity are among documented applications.
| Form | Lyophilized Powder |
|---|---|
| Dosage Per Vial | 2mg |
| Molecular Weight | 5135.9 g/mol |
| CAS Number | 218949-48-9 |
| Purity | ≥99% (HPLC verified) |
| Storage | Store at −20°C. Reconstitute with sterile water. Use within 24–48 hours of reconstitution. |
| Research Use | In vitro / laboratory research only |
Submit a research inquiry and our team will respond within one business day.
Submit Research Inquiry →